Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (43,513)	$ (22,127)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,770	1,813
Depreciation expense	1,001	95
Gain on disposal of assets		(45)
Changes in assets and liabilities:
Prepaid expenses and other current assets	(847)	(1,013)
Operating lease right-of-use assets	946	894
Other assets	(500)	(118)
Accounts payable	2,350	345
Accrued expenses and other current liabilities	1,244	(87)
Operating lease liabilities	(986)	(900)
Deferred revenue	11,715
Net cash used in operating activities	(25,820)	(21,143)
Cash flows from investing activities:
Purchases of property and equipment	(3,385)	(1,775)
Net cash used in investing activities	(3,385)	(1,775)
Cash flows from financing activities:
Proceeds from initial public offering, net of underwriting discount		59,892
Payment of initial public offering costs		(2,383)
Payment of deferred offering expenses	(245)
Proceeds from exercise of stock options	604	8
Net cash provided by financing activities	359	87,703
Net (decrease) increase in cash and cash equivalents	(28,846)	64,785
Cash and cash equivalents and restricted cash, beginning of period	74,922	10,137
Cash and cash equivalents and restricted cash, end of period	46,076	74,922
Supplemental disclosure of non-cash financing and investing activities:
Property and equipment purchases included in accounts payable	41	205
Conversion of redeemable convertible preferred stock		160,227
Accretion of redeemable convertible preferred stock to redemption value		115
Right-of-use asset obtained in exchange of operating lease obligation		13
Other assets included in accounts payable	15
Deferred offering costs included in accounts payable and accrued expense	$ 2
Series C Preferred Stock
Cash flows from financing activities:
Proceeds from the sale of Series C redeemable convertible preferred stock		30,392
Payment of offering costs related to sale of Series C redeemable convertible preferred stock		(206)
Supplemental disclosure of non-cash financing and investing activities:
Allocation of Series C redeemable convertible preferred stock to common stock warrant		$ 740